Lv21
110 积分 2024-05-08 加入
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
1小时前
已完结
ATM and p53 in aging and cancer: a double-edged sword in genomic integrity
1个月前
已完结
Mantle-Cell Lymphoma
11个月前
已完结
[The guideline of the diagnosis and treatment of mantle cell lymphoma in China (2022)]
11个月前
已完结
Global patterns of non‐Hodgkin lymphoma in 2020
11个月前
已完结
Chronic lymphocytic leukaemia
11个月前
已完结
Expert consensus on the management of chronic lymphocytic leukaemia in Asia
11个月前
已完结
Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
11个月前
已关闭
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study
11个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1年前
已完结
皖公网安备34019202002308
